You have 9 free searches left this month | for more free features.
Clincosm LogoSign in Get a demo

AML, acute myeloid leukemia, guadecitabine, SGI-110, Phase 3

Showing 1 - 25 of >10,000
STUDY
CONDITIONS
INTERVENTIONS
LOCATIONS
LAST UPDATED

Untreated Adult Acute Myeloid Leukemia Trial in Houston (Cladribine, Guadecitabine, Idarubicin)

Completed
Has Results
  • Untreated Adult Acute Myeloid Leukemia
  • Houston, Texas
    M D Anderson Cancer Center
Apr 28, 2022

Acute Myeloid Leukemia Refractory, Acute Myeloid Leukemia, in Relapse Trial in Xuzhou (anti Tim-3/CD123 CAR-T cell therapy)

Recruiting
  • Acute Myeloid Leukemia Refractory
  • Acute Myeloid Leukemia, in Relapse
  • anti Tim-3/CD123 CAR-T cell therapy
  • Xuzhou, Jiangsu, China
    Kailin Xu
Nov 4, 2023

Acute Myeloid Leukemia Trial (ABBV-787)

Not yet recruiting
  • Acute Myeloid Leukemia
  • (no location specified)
Sep 29, 2023

Acute Myeloid Leukemia (AML) Trial in Austria, Italy, Spain (Ivosidenib Oral Tablet, Azacitidine)

Not yet recruiting
  • Acute Myeloid Leukemia (AML)
  • Vienna, Austria
  • +3 more
Jun 8, 2023

Acute Myeloid Leukemia (AML) Trial in Birmingham, San Francisco, New York (ZN-d5 ZN-c3, ZN-c3)

Recruiting
  • Acute Myeloid Leukemia (AML)
  • Birmingham, Alabama
  • +2 more
Jan 3, 2023

AML, Adult Trial (STI-8591)

Not yet recruiting
  • AML, Adult
  • (no location specified)
Jul 12, 2023

Acute Myeloid Leukemia Trial in Suzhou (Venetoclax, Homoharringtonine, Cytarabine)

Recruiting
  • Acute Myeloid Leukemia
  • Suzhou, Jiangsu, China
    Qiu Huiying
Mar 28, 2023

AML, Adult, Minimal Residual Disease Trial in Tianjin (CD33/CLL1 dual CAR-NK cell, Cyclophosphamid, Fludarabine)

Not yet recruiting
  • AML, Adult
  • Minimal Residual Disease
  • CD33/CLL1 dual CAR-NK cell
  • +5 more
  • Tianjin, China
    Institute of Hematology & Blood Diseases Hospital
Aug 4, 2023

Acute Myeloid Leukemia, Acute Myeloid Leukemia Recurrent, Leukemia Trial in Boston (Cytokine-Induced Memory-like Natural Killer

Not yet recruiting
  • Acute Myeloid Leukemia
  • +3 more
  • Cytokine-Induced Memory-like Natural Killer Cells
  • +2 more
  • Boston, Massachusetts
  • +1 more
Nov 22, 2023

Acute Myeloid Leukemia Trial in Houston (Azacitidine, Venetoclax, NK Cells)

Not yet recruiting
  • Acute Myeloid Leukemia
  • Houston, Texas
    M.D. Anderson Cancer Center
Apr 17, 2023

Acute Myeloid Leukemia, in Relapse, Acute Myeloid Leukemia Refractory, Granulocytic Sarcoma Trial in Winston-Salem (drug,

Not yet recruiting
  • Acute Myeloid Leukemia, in Relapse
  • +2 more
  • CPI 613
  • +3 more
  • Winston-Salem, North Carolina
    Wake Forest Baptist Comprehensive Cancer Center
May 10, 2023

AML, AML With Mutated NPM1, Hematologic Malignancy Trial (Ziftomenib, Fludarabine, Idarubicin)

Not yet recruiting
  • AML
  • +11 more
  • (no location specified)
Aug 14, 2023

Acute Myeloid Leukemia With FLT3/ITD Mutation Trial in Tampa (Gilteritinib, Vyxeos)

Suspended
  • Acute Myeloid Leukemia With FLT3/ITD Mutation
  • Tampa, Florida
    Moffitt Cancer Center
Nov 11, 2022

Acute Myeloid Leukemia in Remission, FLT3 Gene Mutation, Hematologic and Lymphocytic Disorder Trial in Houston (Azacitidine,

Recruiting
  • Acute Myeloid Leukemia in Remission
  • +5 more
  • Houston, Texas
    M D Anderson Cancer Center
Dec 13, 2022

Acute Myeloid Leukemia With FLT3/ITD Mutation Trial (XY0206, Salvage Chemotherapy)

Not yet recruiting
  • Acute Myeloid Leukemia With FLT3/ITD Mutation
  • (no location specified)
May 24, 2023

Acute Myeloid Leukemia Trial (Gilteritinib 40 MG Oral Tablet, Cladribine, Cytarabine)

Not yet recruiting
  • Acute Myeloid Leukemia
  • Gilteritinib 40 MG Oral Tablet
  • +4 more
  • Lexington, Kentucky
    University of Kentucky
Oct 27, 2022

Acute Myeloid Leukemia, Mixed Lineage Acute Leukemia, Mixed Lineage Leukemia Gene Mutation Trial (Ziftomenib, Venetoclax,

Not yet recruiting
  • Acute Myeloid Leukemia
  • +10 more
  • (no location specified)
Feb 17, 2023

CBFA2T3-GLIS2-positive Acute Myeloid Leukemia, AML, Childhood, Relapsed Pediatric AML Trial (ELU001)

Not yet recruiting
  • CBFA2T3-GLIS2-positive Acute Myeloid Leukemia
  • +3 more
  • (no location specified)
Nov 14, 2022

Leukemia, Myeloid, Acute Trial in Chengdu (Chidamide)

Recruiting
  • Leukemia, Myeloid, Acute
  • Chengdu, Sichuan, China
    West China Hospital of Sichuan University
Dec 27, 2022

Leukemia, Relapsed, Myeloid Trial in Netherlands, Switzerland (MP0533 (multispecific DARPin CD3 Engager Targeting CD33, CD123

Recruiting
  • Leukemia
  • +3 more
  • MP0533 (multispecific DARPin CD3 Engager Targeting CD33, CD123 and CD70)
  • Amsterdam, Netherlands
  • +4 more
Jan 4, 2023

AML/MDS, Acute Myeloid Leukemia, MDS Trial (Danvatirsen, Danvatirsen + Venetoclax)

Not yet recruiting
  • AML/MDS
  • +2 more
  • (no location specified)
Aug 14, 2023

Elderly AML Patients, Unfit, New-diagnosis AML, Acute Myeloid Leukemia Trial in Kunming (Experimental: Venetoclax in combination

Not yet recruiting
  • Elderly AML Patients
  • +4 more
  • Experimental: Venetoclax in combination with Decitabine (+-sorafenib)
  • Active Comparator: Standard dose of Venetoclax + Azacitidine
  • Kunming, Yunnan, China
    The Second Affiliated Hospital of Kunming Medical University.
Oct 3, 2023

Acute Myeloid Leukemia (AML), Acute Lymphoblastic Leukemia (ALL) Trial in Guediawaye GOL SUD (Pyronaridine Tetraphosphate)

Recruiting
  • Acute Myeloid Leukemia (AML)
  • Acute Lymphoblastic Leukemia (ALL)
  • Pyronaridine Tetraphosphate
  • Guediawaye GOL SUD, Dakar, Senegal
    Dalal Jamm Hospital
Nov 23, 2022

Acute Myeloid Leukemia Trial in Kunming (Venetoclax in combination with azacitidine and CAG)

Recruiting
  • Acute Myeloid Leukemia
  • Venetoclax in combination with azacitidine and CAG
  • Kunming, Yunnan, China
    920th Hospital of Joint Logistics Support Force of People's Libe
Dec 20, 2022

Acute Myeloid Leukemia, Relapsed Acute Myeloid Leukemia, Refractory Acute Myeloid Leukemia Trial in United States (Lanraplenib,

Recruiting
  • Acute Myeloid Leukemia
  • +2 more
  • Los Angeles, California
  • +3 more
Aug 4, 2022